Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Risico op COVID-19 wisselt bij opgenomen patiënten met reumatische ziekte
jun 2020 | Artritis, RA, SLE